Psychiatry professor believes that psilocybin has potential to reset the behaviours and cognitions of those with eating disorders by changing neural pathways.

Magic mushrooms’ for eating disorders? Drug company running trials at B.C. university

Dr. C. Laird Birmingham, Psychiatry professor with expertise in eating disorders, believes that psilocybin has potential to reset the behaviours and cognitions of those with eating disorders by changing neural pathways. NeonMind Biosciences Inc. is working with Dr. Birmingham at the University of British Columbia in preclinical trials to determine if psilocybin could be used to change the unconscious response to emotional situations that can trigger food-related addictions.

PDF of article

BETTER PLANT APPOINTS PURE PRODUCT BROKERS FOR SALES IN U.S., AUSTRALIA AND JAPAN

Vancouver, B.C. – January 26, 2021: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) is pleased to announce it has engaged Pure Product Brokers for sales representation for Better Plant’s Urban Juve products, commencing immediately.

Urban Juve is a plant-based skincare line based on Ayurveda and holistic healing principles. Urban Juve has a complete line of face serum, face moisturizers, face mists, body oils, and a lip balm that are crafted plant-based ingredients.

Pure Product Brokers Founder and President, Maureen Malloy, is trained as a Registered Nurse in the state of California and has 25 years of experience in the Beauty and Wellness industry growing multiple brands into retail successes at a national level. “I always look at a brand in terms of balance of innovation and familiarity, whether it’s in formulation, packaging or marketing style,” says Ms. Malloy. “Urban Juve is right on time with this super-intelligent skincare system. No one has done Ayurvedic formulation to this level of quality before.”

Pure Product Brokers represent a wide range of carefully chosen brand partners in the natural skincare space and has successfully launched brands at a national level with such retailers as Sephora and Nordstrom.

“In addition to sharing our company values, Maureen and her team have a proven track record of success and are well-respected for their work in the beauty industry,” says Amber Allen, Director of Sales for Better Plant. “I look forward to uniting our efforts to bring Urban Juve to new markets and diversifying our distribution channels to reach more customers.”

As sales representatives, Pure Product Brokers will solicit orders for Urban Juve products in the US, Australia, Japan, and any additional regions mutually agreed to by both parties. Under the agreement Pure Products will engage in the sales and promotion of products to develop initiate and increase volume of business for Urban Juve, provide continual education to regional and headquarter buyers and retail sales teams, coordinate launch and seasonal education events and educational support for retail sales teams, and consult Urban Juve on best practices required to create a successful product launch within the targeted channels of business and within specific key account formats.

 

About Better Plant Sciences Inc.

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of its products. Its all-natural products vary in use from pain treatment to disease prevention to skin care, all without chemicals or harmful ingredients. It has an extensive catalogue of over 400 proprietary product formulas. Better Plant currently has over 70 plant-based products for sale through eCommerce and/or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also owns approximately 29% of NeonMind Biosciences Inc.

For more information on Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.  Buy Urban Juve products at urbanjuve.com or follow @urbanjuve on Instagram.

 

Penny White, President & CEO

penny@betterplantsciences.com

1-833-515-2677

 

Investor Relations:

Alexandra Dumanski

invest@betterplantsciences.com

1-833-515-2677

 

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

BETTER PLANT AFFILIATE NEONMIND LISTS ON THE FRANKFURT STOCK EXCHANGE (FSE: 6UF)

Vancouver, B.C. – January 19, 2021: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce its partially owned subsidiary NeonMind (CSE: NEON) (“NeonMind”) has common shares now trading on the Frankfurt Stock Exchange (the “FSE”) under the symbol “6UF“. As a result, NeonMind’s common shares are now cross-listed on the Canadian Securities Exchange and the FSE.  Shares of Better Plant are available on the FSE under the symbol “YG3”.

The Frankfurt Stock Exchange is one of the world’s largest trading centres for securities. With a share in turnover of around 90 per cent, it is the largest of Germany’s seven stock exchanges and it is an international trading centre, which is reflected in the structure of its participants. Of the approximately 200 market participants, roughly 50% are from countries other than Germany.

The FSE facilitates advanced electronic trading, settlement and information systems, allowing it to meet the growing requirements of cross-border trading.

 

About NeonMind Biosciences Inc.

NeonMind is a preclinical psychedelic drug development company. Its first proposed drug candidate involves the administration of psilocybin (a complex organic compound found in psychedelic mushrooms) as a treatment for obesity and related illnesses for which NeonMind is conducting a preclinical trial at the University of British Columbia. NeonMind has filed five U.S. provisional patent applications claiming methods of aiding in weight loss, treating compulsive eating disorder, treating obesity or a complication of obesity, and/or altering the diet of an individual by administering psilocybin and/or other psychedelic compounds or their analogues or by administering psilocybin or its analogue in conjunction with therapy or other treatments.  NeonMind is also pursuing commercialization of its catalogue of proprietary medicinal mushroom product formulas. It recently launched a collection of four mushroom-infused coffees containing medicinal mushrooms Lion’s Mane, Turkey Tail, Reishi and Cordyceps which are available for purchase online in Canada at www.neonmind.com.

For more information on NeonMind, go to www.NeonMindbiosciences.com or buy NeonMind mushroom infused coffee at www.NeonMind.com.

 

 

About Better Plant Sciences Inc.

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of its products. Its all-natural products vary in use from pain treatment to disease prevention to skin care, all without chemicals or harmful ingredients. It has an extensive catalogue of over 400 proprietary product formulas. Better Plant currently has over 70 plant-based products for sale through eCommerce and/or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also owns approximately 29.2% of NeonMind.

 

For more information on Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Penny White, President & CEO

penny@betterplantsciences.com

1-833-515-2677

 

Investor Relations:

Alexandra Dumanski

invest@betterplantsciences.com

1-833-515-2677

 

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

BETTER PLANT AFFILIATE NEONMIND TO COMPLETE FULLY SUBSCRIBED IPO AND COMMENCE TRADING ON MONDAY, JANUARY 4, 2021 UNDER THE SYMBOL NEON

Vancouver, B.C. –  December 29, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) announces the common shares of its partially owned subsidiary NeonMind Biosciences Inc. (“NeonMind“) are now approved for trading on the Canadian Securities Exchange (the “Exchange”) as a new listing under the stock ticker symbol “NEON”.  NeonMind expects to close its fully subscribed Initial Public Offering on December 30, 2020 and commence trading on the Exchange under the symbol “NEON” on Monday, January 4, 2021.

The listing of NeonMind on the Exchange will not affect the listing of Better Plant and Better Plant’s common stock will continue to trade on the Exchange under the ticker symbol “PLNT”, and continue to trade on the OTCQB under the ticker symbol “VEGGF”.   Better Plant owns 33,313,500 common shares in NeonMind, which are  subject to an escrow agreement which releases the shares for transfer in tranches over a 3 year period, in accordance with National Policy 46-201.

More information on NeonMind and the NeonMind IPO can be found in NeonMind’s final prospectus which is available on SEDAR at www.sedar.com under issuer information for NeonMind Biosciences Inc.

 

About NeonMind Biosciences Inc.

NeonMind plans to help people change their lives by changing their minds, through treatment with psychedelics.  It is tackling one of the biggest health issues the world is facing right now: obesity. It’s an epidemic that is responsible for 37% of the global burden of disease, according to the World Health Organization. NeonMind is engaged in research to develop a patent pending treatment using psilocybin (a complex organic compound found in psychedelic mushrooms) to cause weight loss. It commenced a Preclinical Trial in November 2020 at the University of British Columbia after Health Canada granted authorization to the Principal Investigator to use psilocybin for NeonMind’s Preclinical Trial.

NeonMind has filed 5 US provisional patent applications claiming methods of aiding in weight loss, treating compulsive eating disorder, treating obesity or a complication of obesity,  and/or altering the diet of an individual by administering psilocybin and/or other psychedelic compounds or their analogs or by administering psilocybin or its analog in conjunction with therapy or other treatments.

NeonMind has also commercialized a collection of 4 coffees infused with medicinal mushrooms Lion’s Mane, Turkey Tail, Reishi and Cordyceps, which are available for purchase in Canada at www.neonmind.com.

 

About Better Plant Sciences Inc. 

Better Plant offers a collection of high-efficacy, plant-based products for optimum health and wellness. It creates formulations with the highest quality, natural raw ingredients, combining modern science with nature to create highly-effective, results-driven products for the mind, body and home.

It is a vertically-integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of its products.  Better Plant is committed to staying at the forefront of plant-science research and development, and is constantly engaged in research to further expand its portfolio of over 400 proprietary formulations and over 70 SKUs which are currently for sale. Its all natural formulas are designed for health optimization, all without chemicals or harmful ingredients.  Better Plant also supports and develops companies with products or services that can help create a better planet, with healthier and happier people.  Its minority owned subsidiary NeonMind Biosciences is  developing treatments with psychedelics and has commercialized  a line of plant-based coffees infused with health optimizing medicinal mushrooms which are for sale at www.neonmind.com.  Better Plant operates the direct to consumer platforms www.getjusu.com and www.urbanjuve.com.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Director of Investor Relations

invest@betterplantsciences.com 

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the closing of the NeonMind IPO, the listing of NeonMind on the Exchange, risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

BETTER PLANT AFFILIATE NEONMIND ANNOUNCES FILING OF FINAL PROSPECTUS IN CONNECTION WITH AN INITIAL PUBLIC OFFERING

Vancouver, B.C. – December 10, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) announces that on December 9, 2020 its majority owned subsidiary NeonMind Biosciences Inc. (“NeonMind“) obtained a receipt for a final prospectus for an initial public offering (the “NeonMind IPO”) for the sale of up to 46,000,000 units at $0.10 per unit (the “Units”) to generate gross proceeds of up to $4,600,000, in conjunction with a conditional approval for listing on the Canadian Securities Exchange (the “Exchange”). The Units are being offered for sale to the public in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario through NeonMind’s agent, Mackie Research Capital Corporation.

 

No securities in Better Plant are being sold as part of the NeonMind IPO offering. The listing of NeonMind on the Exchange will not affect the listing of Better Plant and Better Plant’s common stock will continue to trade on the Exchange under the ticker symbol “PLNT”, and continue to trade on the OTCQB under the ticker symbol “VEGGF”.

 

The NeonMind IPO is subject to a minimum subscription of 20,000,000 Units (the “Minimum Subscription Amount”). The Exchange granted NeonMind conditional approval to its common shares for trading on the Exchange, subject to a number of conditions, including raising the Minimum Subscription Amount. Each Unit will consist of one common share in the capital of NeonMind (a “NeonMind Share”) and one share purchase warrant to purchase one additional NeonMind Share of NeonMind at a price of $0.20 per share for a period of 12 months from the closing of the NeonMind IPO. Upon the successful completion of the NeonMind IPO and subject to regulatory approval, it is anticipated that NeonMind Shares will be listed for trading on the Exchange under the stock symbol “NEON”. Better Plant currently owns 33,313,500 NeonMind Shares out of 66,430,500 NeonMind Shares currently issued and outstanding. Better Plant also owns 55,000,0000 warrants (the “NeonMind Warrants”) to purchase NeonMind Shares at $0.20 per share until May 6, 2022. The NeonMind Shares and NeonMind Warrants owned by Better Plant are subject to an escrow agreement whereby the securities will be released in tranches over a 35 month period, beginning 30 days after the date NeonMind’s common shares begin to trade on the Exchange. Currently, Better Plant owns approximately 50.1% of the outstanding and issued NeonMind Shares. Under the NeonMind IPO, up to an additional 46,000,000 NeonMind Shares could be issued, assuming the over-allotment option is exercised, resulting in up to 112,430,500 NeonMind Shares issued and outstanding, which could reduce Better Plant’s ownership percentage in NeonMind to as low as 29.6%. There is no guarantee that NeonMind will achieve the Minimum Subscription Amount required to complete the NeonMind IPO.

 

NeonMind is developing products that contain legal medicinal mushrooms and it is engaged in preclinical research into potentially therapeutic uses of compounds found in psychedelic mushrooms. NeonMind has filed 5 US provisional patent applications claiming methods of aiding in weight loss, treating compulsive eating disorder, treating obesity or a complication of obesity, and/or altering the diet of an individual by administering psilocybin and/or other psychedelic compounds or their analogs or by administering psilocybin or its analog in conjunction with therapy or other treatments. NeonMind’s long-term goal is to develop one or more products that incorporate restricted psychedelic substances to treat illness, with its product candidate being developed to treat obesity and promote or cause weight loss.

 

More information on NeonMind and the NeonMind IPO can be found in NeonMind’s final prospectus which is available on SEDAR at www.sedar.com under issuer information for NeonMind Biosciences Inc.

 

No securities regulatory authority has either approved or disapproved the contents of this news release. This news release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale or any acceptance of an offer to buy these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities under the IPO have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or the securities laws of any state of the United States and may not be offered, sold or delivered, directly or indirectly, in the United States or to, or for the account of benefit of, U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act), except pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or solicitation of an offer to buy any of these securities in any jurisdiction in which the offering or sale is not permitted.

 

About Better Plant Sciences Inc.

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of our products. Its all-natural products vary in use from pain treatment to disease prevention to skin care, all without chemicals or harmful ingredients. It has an extensive catalogue of over 400 proprietary product formulas. Better Plant currently has over 75 plant-based products for sale through eCommerce and/or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also owns approximately 51% of NeonMind.

 

For more information about Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram. Buy Jusu plant-based home and body products at getjusu.com and buy plant-based Urban Juve skin care products at urbanjuve.com.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Director of Investor Relations

invest@betterplantsciences.com

1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen. Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

BETTER PLANT SUBSIDIARY JUSU LAUNCHES 8 NEW JUICES

Vancouver, B.C. – December 1, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce the launch of eight new Jusu juices. The juices are now for sale at the Cadboro Bay Jusu Bar location at 2560B Sinclair Road in Victoria, British Columbia. The juices will later be available online for direct to consumer sales and delivery in select cities.

 

The Cadboro Bay Jusu Bar recently celebrated its sixth anniversary of operations. “The store has a consistent and loyal local customer base, and has had the same manager since the store opened, who is known and loved by the customers,” says Joelle Fiorito, Head of Operations for Better Plant.

 

The initial order was for 1,000 bottles, which will provide the Better Plant team with key customer feedback in support of the direct to consumer launch of the new Jusu juices.

 

The following eight 355mL cold-pressed Jusu juices are now available at the Cadboro Bay Jusu Bar location:

 

  • Hallelujah (Spinach, Cucumber, Celery, Apple, Ginger and Lemon)
  • I can C clearly now (Turmeric, Apple, Pear, Carrot, Lemon and Ginger)
  • Beet it! (Beet orange carrot ginger)
  • My heart will go on (Kale, Spinach, Apple, Cucumber, Celery, Lemon and Ginger)
  • Smoke on the Water (Pure lemon, Activated Charcoal and Agave)
  • Sweet Alkaline (Blueberry, Cranberry, Strawberry, Apple and Apple Cider Vinegar)
  • I Will Survive (Pure Lemon, Honey and Ginger)
  • Here Comes the Sun (Orange, Ruby Grapefruit, Lemon, Lime and Cayenne)

 

Better Plant plans to market the new juices online through Google ads and a targeted social media campaign, which will  include video advertisements intended to educate consumers on a plant-based lifestyle.

 

The global cold-pressed juices market is expected to post a compound annual growth rate of close to 8% during the period 2019-2023, according to the latest market research report by Technavio. According to the report’s segmentation analysis, the North America region led the market in 2018, followed by Europe, APAC, South America, and MEA respectively. The market in North America is driven by the high demand for healthy beverages that contain no added sugar and artificial preservatives in the region.

 

Better Plant acquired Jusu assets on October 9th. More details on the acquisition are available in the press release Better Plant Completes Acquisition of Jusu, dated October 14th.

 

About Jusu Wellness Inc.

Jusu Wellness Inc. is a wholly owned subsidiary of Better Plant and it owns and operates Jusu, a full spectrum wellness brand with a mission to enlighten consumers to the protective and effective properties of plant-based products. Jusu takes a 360 degree approach to wellness. What you put in your body, on your body and in your environment. Jusu is committed to making pure, organic, plant-based products for consumption, body, and personal care. This includes one JUSU Bar location in Victoria, BC and brick-and-mortar juice bar franchise opportunities as well as an extensive direct-to-consumer product offering including cold-pressed juices, skin care and body products, aromatherapy, and home cleaning lines. Jusu is fully dedicated to offering consumers healthier alternatives to currently available chemical-based skin care, edible, and beverage products.

 

About Better Plant Sciences Inc. 

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of our products. Its  all-natural products vary in use from pain treatment to disease prevention to skin care, all without chemicals or harmful ingredients.  It has an extensive catalogue of over 400 proprietary product formulas.  Better Plant currently has over 60 plant-based products for sale through eCommerce or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also owns approximately 52% of NeonMind Biosciences Inc. NeonMind Biosciences Inc. has manufactured a line of coffees infused with medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product to aid in or cause weight loss and treat obesity and related illnesses.

Health Canada has approved NeonMind’s preclinical trial for research into using psilocybin as a treatment to promote and cause weight loss and NeonMind is currently developing protocols for Phase II human trials to be submitted for approval in early 2021.

NeonMind’s product candidates with psychedelic compounds will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed. Psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (CDSA) and it is a criminal offence to possess substances under the CDSA without a prescription. Health Canada has not approved psilocybin as a drug.

For more information about Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.

Go to getjusu.com to buy Jusu products.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com 

1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

BETTER PLANT LAUNCHES URBAN JUVE LOYALTY PROGRAM WITH LOYALTYLION

Vancouver, B.C. – November 24, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce the launch of  a customer rewards program called “Insider Rewards” for its Urban Juve skin care line.

“Insider Rewards will give our customers the opportunity to collect points to earn free products and also provide access to exclusive promotions,” said Gabriel Villablanca, Director of eCommerce for Better Plant. “Our objective is to turn customers into repeat and loyal customers, and ultimate advocates of the brand and our products.”

LoyaltyLion is a loyalty program platform that supports eCommerce growth by unlocking insights that make it possible to amplify marketing efforts while making customers feel valued. LoyaltyLion has a track record of producing higher customer spend and increasing repeat purchase rates.

“Customers who are members are more likely to purchase more items than nonmember customers without an account,” added Villablanca. “So offering a wide range of rewards in exchange for brand engagement, can pay dividends. Brand engagement activities could include signing up for Urban Juve emails, leaving product reviews, and following Urban Juve on social media platforms.”

The loyalty program also offers a mobile-optimized referral tool to help gain new high value customers at a low acquisition cost. The Company plans to offer Insider Rewards across all brands and will leverage the LoyaltyLion platform for the program.

A 2019 KPMG survey reported that 81% of millennial consumers say they spend more with a company when they are a member of a loyalty program, and 78% say they would switch to a company that offered a better program.

 

About Better Plant Sciences Inc.

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of our products. Its  all-natural products vary in use from pain treatment to disease prevention to skin care, all without chemicals or harmful ingredients.  It has an extensive catalogue of over 400 proprietary product formulas.  Better Plant currently has over 60 plant-based products for sale through eCommerce or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also owns approximately 52% of NeonMind Biosciences Inc. NeonMind Biosciences Inc. has manufactured a line of coffees infused with medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product to aid in or cause weight loss and treat obesity and related illnesses.

Health Canada has approved NeonMind’s preclinical trial for research into using psilocybin as a treatment to promote and cause weight loss and NeonMind is currently developing protocols for Phase II human trials to be submitted for approval in early 2021.

NeonMind’s product candidates with psychedelic compounds will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed. Psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (CDSA) and it is a criminal offence to possess substances under the CDSA without a prescription. Health Canada has not approved psilocybin as a drug.

For more information about Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.

Go to urbanjuve.com to join the customer rewards program and to buy Urban Juve products.

 

Investor Relations Contact

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com 

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

NEONMIND COMMENCES PRECLINICAL TRIAL TO EXAMINE PSILOCYBIN FOR WEIGHT LOSS

Vancouver, B.C. – November 19, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce that its majority owned subsidiary NeonMind Biosciences Inc. (“NeonMind”) has now commenced a psilocybin preclinical trial examining psilocybin as a potential treatment to promote and cause weight loss and to reduce food cravings (the “Trial”) after obtaining Health Canada approval. The Trial is being conducted by the University of British Columbia pursuant to a fee for service agreement.

“We are thrilled to be moving forward with our preclinical trial,” said Penny White, CEO of Better Plant. “We plan to use the data from this trial to support our pending patents and to help inform the protocol development for a Phase 2 human trial.”

NeonMind has filed 4 US provisional patent applications covering the use of psilocybin and other psychedelic substances to promote and cause weight loss, reduce food cravings, treat compulsive eating disorder, improve quality of diet, treat or regulate obesity-associated diabetes,  treat obesity-associated abnormal regulation of blood glucose and aid in the prevention of heart disease, high blood pressure and other obesity-associated illnesses. Its first psilocybin and weight loss related patent was filed in December 2019.

“Psilocybin is known to activate serotonin receptors,” says Dr. William Panenka, scientific advisor to NeonMind. “As a neurotransmitter, serotonin helps to relay messages from one area of the brain to another. Serotonin is responsible for some of the drivers which govern eating. We are very interested in furthering studies to test various dosing and timing regimens for NeonMind to see the effects that psilocybin may have on the regulation of food cravings, weight loss, and glucose-insulin metabolism.”

Obesity has been formally recognized by the World Health Organization (WHO) as a global epidemic, with at least 2.8 million people dying each year as a result of being overweight or obese. The WHO reported that in 2016, more than 1.9 billion adults, 18 years and older, were overweight.

 

About NeonMind Biosciences Inc.

The NeonMind team marries ancient Ayurvedic wisdom with modern science, delivering high quality formulations that put health and wellness at the forefront for each of its unique coffee blends. In addition to its medicinal mushroom products, NeonMind is developing patent pending intellectual property for therapeutic uses of psilocybin, the psychedelic substance in magic mushrooms. Health Canada has approved NeonMind’s preclinical trial for research into using psilocybin as a treatment to promote and cause weight loss and NeonMind is currently developing protocols for Phase II human trials to be submitted for approval in early 2021.

NeonMind’s product candidates with psychedelic compounds will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed. Psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (CDSA) and it is a criminal offence to possess substances under the CDSA without a prescription. Health Canada has not approved psilocybin as a drug.

 

About Better Plant Sciences Inc.

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of our products.  Its all-natural products vary in use from pain treatment to disease prevention to skin care, all without chemicals or harmful ingredients.  It has an extensive catalogue of over 400 proprietary product formulas.  Better Plant currently has over 60 plant-based products for sale through eCommerce or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also owns approximately 52% of NeonMind Biosciences Inc.

For more information about Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com

1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

BETTER PLANT LAUNCHES NEW JUSU ECOMMERCE SITE

Vancouver, B.C. – November 17, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (Better Plantor (the “Companyis pleased to announce the launch of the new Jusu eCommerce site at getjusu.com and the Jusu product rebrand following the Company’s recent acquisition of Jusu, which produces a line of plant-based products for consumption, body and personal care.

“I am very excited about the launch of the new getjusu.com website,” says Gabriel Villablanca, Director of eCommerce for Better Plant. “It makes it easy for customers by giving them a one-stop-shop to tap into the vast catalogue of plant-based wellness products that Jusu Wellness has to offer.”

The new website has launched with an initial inventory of 44 newly branded plant-based products and the Company plans to roll out another 55 products from the Jusu catalogue over the next six months.

The site offers a mobile first experience that is designed to increase conversions and improve the customer experience. This is complemented by improved navigation and a customer-centric approach that creates a seamless shopping experience across Jusu’s entire catalogue. It is also equipped with enhanced video features to make for a visually engaging experience.

“We plan to continue to iterate the online experience of the website so that we can create what feels like a partnership between our products, and our amazing customers,” added Villablanca.

The Company will also soon be launching incentives programs, including a rewards program that earns customers points and access to exclusive content. Additional bundles of the most popular products and scents will become available to give customers a chance to try an assortment of similar products together.

 

About Jusu Wellness Inc.

Jusu Wellness Inc. is a wholly owned subsidiary of Better Plant and it owns and operates Jusu, a full spectrum wellness brand with a mission to enlighten consumers to the protective and effective properties of plant-based products. Jusu is committed to making pure, organic, plant-based products for consumption, body, and personal care. This includes one JUSU Bar location in Victoria, BC and brick-and-mortar juice bar franchise opportunities as well as an extensive direct-to-consumer product offering including cold-pressed juices, skin care and body products, aromatherapy, and home cleaning lines. Jusu is fully dedicated to offering consumers healthier alternatives to currently available chemical-based skin care, edible, and beverage products.

 

About Better Plant Sciences Inc.

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of our products.  Its  all-natural products vary in use from pain treatment to disease prevention to skin care, all without chemicals or harmful ingredients.  It has an extensive catalogue of over 400 proprietary product formulas.  Better Plant currently has over 60 plant-based products for sale through eCommerce or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also owns approximately 52% of NeonMind Biosciences Inc. NeonMind has a line of medicinal mushroom coffees, and Health Canada has approved NeonMind’s preclinical trial to support research using psilocybin as a treatment for weight loss. NeonMind has filed 5 U.S. provisional patents to protect its psychedelic research.

For more information about Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.

Go to www.getjusu.com to buy Jusu products.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com 

1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

NEONMIND OBTAINS HEALTH CANADA APPROVAL TO ADVANCE PSILOCYBIN RESEARCH

Vancouver, B.C. – November 12, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) is pleased to announce that its majority owned subsidiary NeonMind Biosciences Inc. (“NeonMind”) has obtained Health Canada approval to advance its preclinical trial on psilocybin-based research (the “Trial”).

The Trial is intended to determine the capacity of psilocybin to dose-dependently cause weight loss and prevent weight gain, measuring glucose metabolism, weight loss and effect on food cravings.

NeonMind has engaged the University of British Columbia (the “University”) to conduct the Trial. The services are provided by the University under the supervision of Dr. Alasdair Barr, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, who is authorized by Health Canada to act as the Principal Investigator for the Trial (the “Principal Investigator”).

Dr. Barr is a tenured faculty member at the University and has extensive experience working with controlled substances as part of his research. His doctoral and post-doctoral research involved a significant body of work using controlled substances.

Before psilocybin, a restricted substance, can be used for a scientific purpose in Canada, the Canadian Minister of Health must grant authority or an exemption pursuant to Subsection 56 of the Controlled Drugs and Substances Act, S.C. 1996, c. 19.

On July 27, 2020, an application regarding the NeonMind Trial was submitted to Health Canada and on October 7, 2020, pursuant to section J.01.059 of Part J of the Food and Drug Regulations (FDR), Health Canada granted authorization to the Principal Investigator to carry out the Trial using psilocybin at UBC.

 

About NeonMind Biosciences Inc.

The NeonMind team marries ancient Ayurvedic wisdom with modern science, delivering high quality formulations that put health and wellness at the forefront for each of its unique coffee blends. In addition to its medicinal mushroom products, NeonMind is developing patent pending intellectual property for therapeutic uses of psilocybin, the psychedelic substance in magic mushrooms. Health Canada has approved NeonMind’s preclinical trial for research into using  psilocybin as a treatment for weight loss and NeonMind is currently developing protocols for Phase II human trials to be submitted for approval in early 2021.

NeonMind’s product candidates with psychedelic compounds will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed. Psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (CDSA) and it is a criminal offence to possess substances under the CDSA without a prescription. Health Canada has not approved psilocybin as a drug.

 

About Better Plant Sciences Inc.

Better Plant Sciences Inc. offers a collection of high-efficacy, plant-based products for optimum health and wellness.  We are a vertically-integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of our products.  We are committed to staying at the forefront of plant-science research and development, and are constantly engaged in research to further expand our portfolio of proprietary formulations and pending patents. Our all natural products vary in use from pain treatment to disease prevention to health optimization, all without chemicals or harmful ingredients.  We have an extensive catalogue of over 400 proprietary product formulas.  We currently have over 80 plant-based products for body, baby, and home for sale through e-commerce or in retail stores under the brands JUSU, Urban Juve, and Wright & Well. Better Plant owns approximately 52% of NeonMind’s issued and outstanding shares.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for Better Plant’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.